AUS
NZ
UK
CA
USA
IND
Highlights
- Clarity inks commercial production deal for copper-64 with Nusano
- Shares rise over 12%, topping ASX 200 leaderboard
- $11.1M tax incentive to boost product development
Clarity Pharmaceuticals (ASX:CU6) saw a notable surge in its share price following a significant announcement regarding a new production agreement. The company revealed it has signed a commercial-scale deal with Nusano, a U.S.-based producer of medical isotopes, for the manufacturing of copper-64—a radioactive isotope critical for cancer diagnostics and treatment.
This agreement marks a key step forward in Clarity’s efforts to strengthen its radiopharmaceutical platform, as copper-64 is central to its targeted cancer imaging and treatment technology. According to the announcement, Nusano will begin producing 18,000 patient doses of copper-64 per day, with operations expected to commence in early 2026. The company highlighted that this partnership ensures a reliable, consistent, and large-scale supply of the isotope, a crucial factor in advancing radiopharmaceutical accessibility in global markets.
On the day of the announcement, shares of Clarity Pharmaceuticals jumped 12.02% to $1.88, making it the top performer on the ASX 200. Despite the strong market reaction, Clarity’s stock is still down 30.04% over the past 12 months, suggesting that recent momentum may be seen as a positive shift in outlook by investors.
Alongside the production agreement, Clarity also reported receiving an $11.1 million refund through Australia’s Research and Development Tax Incentive program. These funds are expected to support continued development of Clarity’s theranostic pipeline, which combines diagnostic and therapeutic uses of copper-based isotopes. The company plans to channel the funding into research programs aimed at bringing its suite of products closer to regulatory and clinical milestones.
Executive chair Alan Taylor emphasized the strategic significance of both the partnership and the funding, noting that Clarity aims to reshape the field of radiopharmaceuticals by aligning production models with those commonly seen in mainstream oncology. He stated that establishing a dependable supply chain is vital for improving patient outcomes and supporting healthcare providers in both diagnostics and treatment.
With commercial-scale isotope production on the horizon and fresh funding to support its pipeline, Clarity Pharmaceuticals appears well-positioned to advance its next phase of development in the growing field of nuclear medicine.
